Sciensus Cancer Services’ Post

You might feel nervous about getting a second opinion, but it’s very common in medicine! This is especially true after a big diagnosis like cancer or if your doctor suggests a major operation. Would you buy a car without considering all your options? You would do your homework and make sure you choose the best one for you. Just because two doctors disagree, that doesn’t mean one is right and one is wrong. Sometimes, you just need to make your decision based on things like how long it will take you to get better, what kind of ongoing care you might need, or how much it costs. This #PatientSafetyAwarenessWeek, download, read, and share 𝘛𝘩𝘦 𝘗𝘢𝘵𝘪𝘦𝘯𝘵’𝘴 𝘊𝘰𝘮𝘱𝘢𝘯𝘪𝘰𝘯, a handbook to help patients better understand their healthcare and help providers better understand their patients: https://lnkd.in/eZKKQvfS

In this edition of In The Network, we introduce MiBA and how MiBA drives informed decision-making to improve patient outcomes. https://hubs.li/Q02Z9G2G0 Read the article > #InTheNetwork #CancerCare #WeAreAON

🔍 Early cancer detection is transforming lives, and with Carci Reagent, you can take a proactive step from the comfort of your home. Our innovative in vitro diagnostic tool is designed for self-testing, offering an initial assessment of your health by detecting indicative levels of tyrosine, a potential marker for malignancies. By harnessing advanced chromogenic methods, Carci Reagent provides reliable results that empower you to monitor your well-being, making it an essential product for those who value health awareness and convenience. Having expanded our market presence globally, our test is recognized and endorsed by the medical community as a valuable preliminary screening tool. Ideal for adults over 18 who prioritize health vigilance, our test is also recommended by healthcare professionals for initial health evaluations. Join the growing community of individuals taking charge of their health. Share this post to spread the word about accessible, proactive healthcare solutions! #CarciReagent #CNEUMedical #CancerDetection #MedicalInnovation #HealthTech #CancerAwareness #FightCancer #testforcancer #prostatecancer #pancreaticcancer www.carcireagent.com

"It is not unusual for a variety of diagnostic tests to be used by healthcare providers to identify elevated risks, diagnose certain conditions, inform the best treatment option, or even measure if a treatment is working. Above all, it is imperative that these tests’ performance and accuracy be well characterized before their results are used for important treatment decisions. Inaccurate or unreliable tests can have significant implications on healthcare cost, system burden, and #patient outcomes." Friends of Cancer Research's President & CEO Jeff Allen live at a Subcommittee on Health hearing titled "Evaluating Approaches to #Diagnostic Test Regulation and the Impact of FDA’s Proposed Rule." Watch here: https://lnkd.in/esx9nf93

Today is the first day of our EPICS #LungCancer strategic meeting in Philadelphia. Contact us to receive your copy of the insights report, capturing treatment recommendations of clinical experts: https://lnkd.in/eY3vFPTA #CancerCare #LungCancerAwarenessMonth

Your Health Companion collects real time longitudinal Patient Reported Outcomes as part of the Digital Assessment Xchange (DAX) research platform. This links to national clinical datasets to support regulatory and reimbursement appraisals. #rwe #medicalaffairs #lungcancer #mesothelioma #HTA #cancerresearch #marketaccess #digitalgealth #heor #patientadvocacy #patientresearch Oliver Webb Vivienne Law Lee Wemyss William Dolben

The new study on scalp cooling efficacy in Asian-predominant populations, found that 50% of patients achieved scalp cooling success. However, it also highlighted differences in success levels depending on the whether the chemotherapy regimen was based on taxanes, anthracyclines, or anthracyclines and cyclophosphamide. Whilst this shouldn’t deter clinicians from prescribing the ideal chemotherapy regimen, it allows them to better manage expectations when it comes to scalp cooling. #ChangingTheFaceOfCancer #ScalpCooling

Exact Sciences recently shared new modeling #data describing the projected impact of the Cologuard test on patients, #healthcare professionals, and the U.S. health care system since its FDA approval 10 years ago. The data assessed the far-reaching benefits of the first and only multi-target stool DNA test for patients, their families, and the health care system. Over the past 10 years, the Cologuard test has been used to screen for colorectal #cancer more than 16 million times. Press Release: 'New modeling data show the Cologuard test has detected more than 623,000 cancers and precancers over past decade, saving U.S. health care system $22 billion' https://lnkd.in/gVJ68a6F #Wisconsin #innovation